Masimo (NASDAQ:MASI – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday.
Several other research analysts have also recently weighed in on MASI. BTIG Research reduced their price target on shares of Masimo from $200.00 to $153.00 in a report on Tuesday, July 18th. Needham & Company LLC reiterated a “buy” rating and issued a $136.00 price target on shares of Masimo in a report on Wednesday, August 9th. Stifel Nicolaus cut shares of Masimo from a “buy” rating to a “hold” rating and reduced their price target for the company from $205.00 to $120.00 in a report on Tuesday, July 18th. Raymond James reduced their price target on shares of Masimo from $198.00 to $142.00 and set an “outperform” rating for the company in a report on Thursday, August 10th. Finally, Wells Fargo & Company reduced their price target on shares of Masimo from $126.00 to $110.00 and set an “equal weight” rating for the company in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $151.33.
Masimo Trading Down 6.3 %
Shares of NASDAQ MASI opened at $98.47 on Wednesday. Masimo has a 1-year low of $98.04 and a 1-year high of $198.00. The company has a market cap of $5.20 billion, a PE ratio of 46.01 and a beta of 0.81. The company has a current ratio of 2.11, a quick ratio of 1.16 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average of $120.93 and a two-hundred day moving average of $155.33.
Masimo (NASDAQ:MASI – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.24). The business had revenue of $455.30 million for the quarter, compared to the consensus estimate of $478.27 million. Masimo had a return on equity of 15.79% and a net margin of 5.30%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period last year, the firm earned $1.35 earnings per share. As a group, equities analysts expect that Masimo will post 3.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the business. WINTON GROUP Ltd raised its position in Masimo by 14.3% during the first quarter. WINTON GROUP Ltd now owns 3,499 shares of the medical equipment provider’s stock worth $646,000 after acquiring an additional 438 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Masimo by 14.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 63,060 shares of the medical equipment provider’s stock worth $11,131,000 after acquiring an additional 7,954 shares in the last quarter. Renaissance Technologies LLC raised its position in Masimo by 275.9% during the fourth quarter. Renaissance Technologies LLC now owns 179,700 shares of the medical equipment provider’s stock worth $26,587,000 after acquiring an additional 131,900 shares in the last quarter. CenterBook Partners LP raised its position in Masimo by 144.9% during the first quarter. CenterBook Partners LP now owns 14,510 shares of the medical equipment provider’s stock worth $2,678,000 after acquiring an additional 8,584 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in Masimo by 3.5% during the first quarter. Daiwa Securities Group Inc. now owns 2,923 shares of the medical equipment provider’s stock worth $539,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.